Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Kinda Al-Hourani, a final year DPhil student in Hal Drakesmith's lab in the MRC Human Immunology Unit, took a poster describing her project ("Activins and antiviral immunity") to the House of Commons a few days ago, to compete in the SET for BRITAIN 2015 Event.  

Kinda presented her poster to a variety of scientists, Members and Lords / Ladies including Andrew Miller MP, Chair of the HoC Science and Technology Committee.  As a result, Kinda received the Silver Medal (and £2000) out of hundreds of entries in the Biological sciences category. http://www.setforbritain.org.uk/2015winners.asp

SET_for_BRITAIN
Copyright SET for BRITAIN

Similar stories

Many Long COVID patients continue to experience symptoms one year after hospital discharge

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge according to the latest results of a major national study.

Spin-out company Alethiomics launches

The enterprise will focus on developing targeted therapies for a specific family of blood cancers.

Interview with Excellence Award winner Dr Susan Shapiro

A member of the Oxford Centre For Haematology, Dr Shapiro, was recently interviewed by the Royal College of Pathologists.

Iron integral to the development of life on Earth – and the possibility of life on other planets

A collaboration between researchers at the MRC WIMM and Department of Earth Sciences uncovers the importance of iron for the development of complex life on Earth.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.